04 May 2017

REDX PHARMA PLC - Notice of Interim Results


Notice of Interim Results

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that its interim results for the six months ended 31st March 2017 will be announced on Wednesday 17th May 2017.

www.redxpharma.com in advance of the call.

For further information, please contact 

Redx Pharma Plc
Neil Murray, Chief Executive Officer
T: +44 1625 469 900

Karl Hård, Head of Investor Relations & Corporate Communications
T: +44 7491 651 406

Cantor Fitzgerald Europe (Nomad & Broker)
Phil Davies/ Michael Reynolds
T: +44 20 7894 7000

WG Partners LLP (Joint Broker)
Claes Spång / Chris Lee / David Wilson
T: +44 20 3705 9330

Consilium Strategic Communications
Amber Fennell/ Matthew Neal/ Melissa Gardiner
T: +44 20 3709 5700

About Redx Pharma Plc

Company website: www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

Back to previous page